Stempoint Capital’s Akero Therapeutics AKRO Stock Holding History

Stempoint Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-121,410	Closed	-$5.76M	–	79
2025 Q3	$5.76M	Buy	121,410 +4,631	+4%	+$224K	1.16%	28
2025 Q2	$6.23M	Sell	116,779 -39,406	-25%	-$1.79M	2%	18
2025 Q1	$6.32M	Buy	+156,185	New	+$6.62M	2.02%	21

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Stempoint Capital's AKRO Position: Q4 2025 in Review

Stempoint Capital sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 121,410 shares — an estimated $5.76M sold.

Stempoint Capital first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $6.32M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Stempoint Capital reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Stempoint Capital sold 121,410 Akero Therapeutics shares in Q4 2025, an estimated $5.76M.
Stempoint Capital first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
Stempoint Capital's Akero Therapeutics position peaked at $6.32M in Q1 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.